Investor Presentaiton

5 Commercial execution and innovation Diabetes care Better outcomes and broader reach can be accomplished through continued innovation, supported by digital solutions Novo Nordisk's product portfolio follows the patient treatment journey OZEMPIC TRESIBA Xultophy Portfolio and pipeline Digital health solutions RYBELSUS® semaglutide tablets semaglutide injection insulin degludec [rDNA origin] injection High dose oral semaglutide Uncontrolled on current OAD Semaglutide 2.0 mg Icodec IcoSema Needing first injectable Needing first basal insulin Needing more than basal insulin Novo PenⓇ6 / Novo Pen Echo® Plus are smart insulin pens and launched in 8 countries CGM: Continuous glucose monitoring; Grey boxes in the portfolio and pipeline references phase 2 or phase 3 assets. Abbott 0 Medtronic 000 600 RYZODEG® Fiasp fast-acting insulin aspart Needing added meal- time insulin control mySugr Roche Partnered with global CGM players glooko Dexcom® CMD22 CAPITAL MARKETS DAY Novo NordiskⓇ

View entire presentation